KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Inventory: 2009-2024

Historic Inventory for Halozyme Therapeutics (HALO) over the last 16 years, with Dec 2024 value amounting to $141.9 million.

  • Halozyme Therapeutics' Inventory rose 41.38% to $185.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $185.8 million, marking a year-over-year increase of 41.38%. This contributed to the annual value of $141.9 million for FY2024, which is 11.17% up from last year.
  • According to the latest figures from FY2024, Halozyme Therapeutics' Inventory is $141.9 million, which was up 11.17% from $127.6 million recorded in FY2023.
  • Halozyme Therapeutics' Inventory's 5-year high stood at $141.9 million during FY2024, with a 5-year trough of $53.9 million in FY2021.
  • In the last 3 years, Halozyme Therapeutics' Inventory had a median value of $127.6 million in 2023 and averaged $123.2 million.
  • Per our database at Business Quant, Halozyme Therapeutics' Inventory surged by 106.91% in 2020 and then declined by 11.26% in 2021.
  • Over the past 5 years, Halozyme Therapeutics' Inventory (Yearly) stood at $60.7 million in 2020, then decreased by 11.26% to $53.9 million in 2021, then skyrocketed by 85.73% to $100.1 million in 2022, then rose by 27.44% to $127.6 million in 2023, then grew by 11.17% to $141.9 million in 2024.